GHK-Cu is a naturally occurring copper-binding tripeptide first identified in human plasma by Loren Pickart in 1973. It is found in blood, saliva, and urine, with plasma levels declining from about 200 ng/mL at age 20 to 80 ng/mL by age 60. The copper ion is essential for its biological activity, as it enables the peptide to serve as a bioavailable copper delivery system.
GHK-Cu exerts its biological effects through multiple well-characterized mechanisms. It powerfully stimulates collagen synthesis (types I and III), decorin, and glycosaminoglycan production in dermal fibroblasts. Simultaneously, it upregulates matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), enabling coordinated tissue remodeling rather than simple collagen deposition. This remodeling capacity is key to its wound-healing effects — GHK-Cu promotes organized tissue repair rather than scar formation.
Beyond structural matrix effects, GHK-Cu has potent antioxidant activity via SOD and glutathione pathway upregulation, suppresses inflammatory cytokines including TGF-beta and TNF-alpha, and promotes angiogenesis by inducing VEGF and FGF-2 expression. Gene expression studies by Pickart et al. using the Broad Institute Connectivity Map showed GHK can influence the expression of over 4,000 genes, with patterns suggesting suppression of fibrosis-related and inflammation-related gene networks.
Key Research Findings
Pickart et al. (2012) demonstrated GHK-Cu affects expression of 4,048 human genes, resetting gene expression patterns associated with aggressive fibrosis and tissue destruction toward healthier profiles.
Leyden et al. (2002) showed topical GHK-Cu cream significantly improved skin laxity, clarity, and reduced fine lines in a 12-week controlled facial study.
Canapp et al. (2003) found GHK-Cu accelerated wound healing in dogs with open wound management, with significantly faster wound contraction.
Siméon et al. (2000) demonstrated GHK-Cu stimulates decorin synthesis by fibroblasts, a proteoglycan critical for proper collagen fiber organization.
Topical studies typically use 1-4% GHK-Cu solutions. In vitro studies use concentrations of 1-10 micromolar. Injectable research protocols are less standardized, with doses varying widely by application.
Storage & Handling
Store lyophilized powder at -20C, protected from light. The copper complex is stable but can oxidize; minimize exposure to air. Reconstituted solution should be refrigerated at 2-8C and used within 30 days.
Frequently Asked Questions
What is GHK-Cu?
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine with a copper ion) found in human plasma. Its concentration declines with age, and it has been extensively studied for roles in skin remodeling, wound healing, and gene expression modulation.
Why is the copper ion important?
The copper (II) ion is essential for GHK-Cu's biological activity. It enables the peptide to serve as a bioavailable copper delivery system, and copper is a critical cofactor for enzymes like lysyl oxidase (which crosslinks collagen) and superoxide dismutase (an antioxidant enzyme).
How many genes does GHK-Cu affect?
Broad Institute Connectivity Map analysis by Pickart et al. found GHK influences the expression of over 4,000 human genes, with significant effects on pathways related to tissue remodeling, inflammation suppression, and antioxidant defense.
The Glow Blend combines three peptides with complementary tissue-repair and skin-remodeling mechanisms. GHK-Cu (copper tripeptide-1) is the primary cosmetic-active component, directly stimulating collagen and glycosaminoglycan synthesis in dermal fibroblasts while modulating matrix metalloproteinases for organized tissue remodeling. Its gene expression effects span over 4,000 genes related to tissue repair, antioxidant defense, and inflammation suppression.
BPC-157 adds a potent pro-angiogenic dimension to the blend. By upregulating VEGF and its receptors, BPC-157 promotes the formation of new blood vessels that are essential for delivering nutrients and oxygen to regenerating tissue. Its interaction with the nitric oxide system provides additional support for vascular function and tissue healing. BPC-157's broad cytoprotective properties complement GHK-Cu's remodeling activity.
TB-500 (thymosin beta-4 fragment) contributes through its unique mechanism of sequestering G-actin monomers and promoting actin polymerization, which is the driving force behind cell migration. In wound healing, cell migration is often the rate-limiting step — keratinocytes and fibroblasts must physically move into the wound bed before repair can occur. TB-500 facilitates this migration while also exhibiting anti-inflammatory effects through suppression of NF-kB-mediated cytokine release. The combination of these three peptides addresses wound healing at multiple levels: vascular supply (BPC-157), matrix remodeling (GHK-Cu), and cellular migration (TB-500).
Key Research Findings
Pickart et al. (2015) showed GHK-Cu resets gene expression patterns associated with tissue destruction toward regenerative profiles, affecting 4,048 genes.
Sikiric et al. (2018) demonstrated BPC-157's broad cytoprotective and angiogenic effects through the NO system across multiple tissue types.
Malinda et al. (1999) showed thymosin beta-4 promotes dermal wound healing by accelerating keratinocyte migration and reducing inflammation in full-thickness wound models.
Siméon et al. (1999) demonstrated GHK-Cu modulates MMP expression in wounds, enabling organized remodeling rather than scar formation.
As a blend, specific ratios vary by formulation. Individual component research doses: GHK-Cu at 1-10 micromolar topically; BPC-157 at 10 mcg/kg in animal models; TB-500 at 6 mg loading dose protocols in equine research.
Storage & Handling
Store lyophilized powder at -20C. Reconstituted solution should be refrigerated at 2-8C and used within 14-21 days. Protect from light to preserve copper complex stability.
Frequently Asked Questions
Why combine GHK-Cu, BPC-157, and TB-500?
Each peptide addresses a different bottleneck in tissue repair. GHK-Cu drives collagen synthesis and matrix remodeling, BPC-157 promotes blood vessel formation (angiogenesis) needed for nutrient delivery, and TB-500 accelerates cell migration into wound sites. Together they address the three major requirements for tissue regeneration.
How does the Glow Blend differ from the Wolverine Blend?
The Glow Blend adds GHK-Cu (a skin-specific copper peptide with extensive cosmetic research) to the BPC-157/TB-500 base of the Wolverine Blend. This gives it a stronger focus on skin remodeling, collagen synthesis, and cosmetic applications.
How does the Glow Blend differ from the Klow Blend?
The Klow Blend includes everything in the Glow Blend plus KPV, an anti-inflammatory alpha-MSH fragment. The KPV addition provides enhanced anti-inflammatory and antimicrobial properties, making the Klow Blend broader in scope.
Source Glow Blend (GHK-Cu / BPC-157 / TB-500) for your research
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Its mechanisms of action are multifaceted and have been studied extensively in over 100 animal studies. A central aspect of its activity involves upregulation of growth factor expression, including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), and their receptors. This pro-angiogenic activity helps explain its remarkable wound-healing and tissue-repair properties observed across multiple tissue types.
BPC-157 also interacts with the nitric oxide (NO) system in a complex, context-dependent manner. It can rescue NO production when it is pathologically inhibited and can attenuate excessive NO when it is overproduced, suggesting a modulatory rather than unidirectional effect. Research by Sikiric et al. has demonstrated that BPC-157 interacts with the dopaminergic system and may counteract both the acute and chronic effects of dopaminergic agents, pointing to direct CNS activity.
At the gastrointestinal level, BPC-157 maintains mucosal integrity by promoting granulation tissue formation and angiogenesis within lesion sites. It has shown cytoprotective effects against NSAID-induced gastric damage, ethanol-induced lesions, and stress ulcers in numerous rodent models. The peptide appears to modulate the FAK-paxillin pathway, which is critical for cell migration and adhesion during wound repair.
Key Research Findings
Sikiric et al. (2011) reviewed decades of research showing BPC-157 heals esophageal, gastric, duodenal, and colonic lesions in rodent models, with efficacy comparable to or exceeding standard treatments.
Chang et al. (2011) demonstrated BPC-157 accelerated healing of transected Achilles tendons in rats by promoting tendon fibroblast outgrowth and VEGF expression.
Seiwerth et al. (2014) showed BPC-157 promoted angiogenesis in a chick embryo CAM assay and accelerated cutaneous wound healing in diabetic rodent models.
Pevec et al. (2010) found BPC-157 improved healing of medial collateral ligament injuries in rats with increased biomechanical strength at the repair site.
Sikiric et al. (2018) demonstrated BPC-157 interacts with the NO system, rescuing impaired healing in L-NAME-treated animals and counteracting excessive NO in L-arginine models.
In rodent studies, BPC-157 is typically administered at 10 mcg/kg or 10 ng/kg, delivered intraperitoneally or locally at the injury site. Oral administration has also been studied for gastrointestinal applications. No human clinical trial data is currently published.
Storage & Handling
Store lyophilized powder at -20C, protected from light. Reconstituted solution should be refrigerated at 2-8C and used within 14-21 days. Use bacteriostatic water for reconstitution.
Frequently Asked Questions
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide derived from a naturally occurring protein in human gastric juice called Body Protection Compound. It has been studied extensively in animal models for its broad tissue-protective and healing properties.
What types of tissue repair has BPC-157 been studied for?
Animal studies have investigated BPC-157 in tendon, ligament, muscle, bone, skin, corneal, and gastrointestinal tissue repair. It has shown pro-healing effects across all these tissue types, which researchers attribute to its pro-angiogenic and growth factor modulatory activity.
Are there human clinical trials for BPC-157?
As of current literature, BPC-157 has been studied primarily in animal models and in vitro systems. While its safety profile in animal studies has been favorable (no reported toxicity at therapeutic doses), published human clinical trial data remains limited.
How does BPC-157 relate to TB-500?
BPC-157 and TB-500 (thymosin beta-4) are often studied in parallel due to their complementary tissue-repair mechanisms. BPC-157 works primarily through angiogenesis and growth factor modulation, while TB-500 promotes cell migration via actin polymerization regulation. This is the rationale behind blend products like the Wolverine Blend.
Source Body Protection Compound-157 for your research
Epitalon is a synthetic tetrapeptide based on the naturally occurring peptide epithalamin, which is extracted from the pineal gland. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, epitalon is the most extensively studied of the Khavinson peptide bioregulators. Its primary mechanism of action involves activation of telomerase, the enzyme responsible for maintaining telomere length at chromosome ends.
Telomeres shorten with each cell division, and this progressive shortening is considered a key hallmark of cellular aging. When telomeres become critically short, cells enter senescence or undergo apoptosis. Khavinson and colleagues demonstrated that epitalon can activate telomerase in human somatic cells, leading to elongation of telomeres and extension of cellular lifespan beyond the Hayflick limit. This was shown in human fetal fibroblast cultures where epitalon-treated cells underwent significantly more population doublings than controls.
Epitalon also influences melatonin production. As a pineal bioregulator, it has been shown to restore the nocturnal melatonin peak in aged primates, which normally declines with age. This melatonin-related activity provides a secondary mechanism through which epitalon may affect aging processes, given melatonin's roles as an antioxidant and circadian regulator.
Key Research Findings
Khavinson et al. (2003) demonstrated epitalon activated telomerase and elongated telomeres in human fetal fibroblasts, extending their replicative lifespan by 44%.
Anisimov et al. (2001) showed chronic epitalon administration extended maximum lifespan and inhibited spontaneous tumor development in female mice.
Khavinson & Morozov (2003) reported that long-term treatment with epithalamin (the natural extract) increased maximum lifespan in aged rhesus monkeys.
Goncharova et al. (2005) demonstrated epitalon restored the nocturnal melatonin peak in old female macaques to levels comparable to young animals.
Animal studies have used doses of 0.1-1 mcg per animal in rodents. In primate studies, epithalamin was administered at doses equivalent to 10-20 mg of the natural extract. In vitro telomerase activation studies used micromolar concentrations.
Storage & Handling
Store lyophilized powder at -20C. Reconstituted solution should be refrigerated at 2-8C. As a small tetrapeptide, epitalon is relatively stable compared to larger peptides.
Frequently Asked Questions
What is Epitalon?
Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) based on epithalamin, a natural pineal gland extract. It was developed by Russian gerontologist Vladimir Khavinson and has been studied primarily for its effects on telomerase activation and aging biomarkers.
What is the relationship between epitalon and telomerase?
Research has shown epitalon can activate telomerase, the enzyme that maintains telomere length. Telomere shortening is a hallmark of cellular aging, and telomerase activation can extend the replicative capacity of cells. Khavinson et al. demonstrated this directly in human fibroblast cultures.
How does N-Acetyl Epitalon Amidate differ from standard Epitalon?
N-Acetyl Epitalon Amidate is a modified version with N-terminal acetylation and C-terminal amidation, modifications designed to increase resistance to enzymatic degradation and potentially improve cellular uptake and bioavailability.
NAD+ is a fundamental coenzyme in cellular energy metabolism, serving as the primary electron carrier in mitochondrial oxidative phosphorylation and as an essential substrate for sirtuins (SIRT1-7), PARPs, and CD38/CD157 enzymes. NAD+ levels decline significantly with age, impairing sirtuin-mediated gene regulation, mitochondrial function, and DNA repair capacity.
The 500mg product contains the same NAD+ compound as the 1000mg biofermented version at a lower quantity. See the NAD 1000mg entry for comprehensive research details on NAD+ biology, the role of NAD+ decline in aging, and the therapeutic potential of NAD+ restoration.
Key Research Findings
Yoshino et al. (2011) showed NAD+ restoration normalizes glucose tolerance and mitochondrial function in aged mice.
Gomes et al. (2013) demonstrated declining NAD+ causes pseudohypoxia through disrupted SIRT1-HIF1alpha signaling.
Verdin (2015) reviewed NAD+ as a central regulator of aging, metabolism, and neurodegeneration.
Rajman et al. (2018) comprehensively reviewed the in vivo evidence for therapeutic NAD+ boosting.
IV NAD+ protocols in clinical settings use 250-750 mg infusions. The 500mg vial provides a standard research quantity.
Storage & Handling
Store lyophilized powder at -20C, protected from light and moisture. NAD+ is hygroscopic. Reconstituted solutions should be used promptly.
Frequently Asked Questions
What is the difference between NAD 500mg and NAD 1000mg Biofermented?
Both contain the same NAD+ coenzyme. The 1000mg biofermented version provides double the quantity and is produced through microbial fermentation for high purity. Choose based on your protocol's quantity requirements.
Source Nicotinamide Adenine Dinucleotide for your research
KPV is the C-terminal tripeptide (amino acids 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite being the smallest anti-inflammatory fragment of alpha-MSH, KPV retains potent anti-inflammatory activity through a unique mechanism that does not require melanocortin receptor binding. This distinguishes it from full-length alpha-MSH and melanotan peptides, which act through MC1R-MC5R receptors.
KPV enters cells and directly inhibits NF-kB activation by preventing the phosphorylation of IkB-alpha and the subsequent nuclear translocation of the NF-kB p65 subunit. By blocking this master inflammatory transcription factor, KPV suppresses the production of a broad array of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-6, IL-8, and nitric oxide. Brzoska et al. demonstrated this intracellular mechanism is independent of cell-surface melanocortin receptor engagement.
KPV also exhibits direct antimicrobial activity against several pathogens including Staphylococcus aureus and Candida albicans. In gastrointestinal research, Kannengiesser et al. showed KPV reduces colonic inflammation in murine colitis models, protecting mucosal integrity and reducing tissue damage. This dual anti-inflammatory and antimicrobial profile makes KPV relevant to IBD research and wound healing applications where infection and inflammation coexist.
Key Research Findings
Brzoska et al. (2008) demonstrated KPV enters cells and directly inhibits NF-kB nuclear translocation independently of melanocortin receptors.
Kannengiesser et al. (2008) showed KPV attenuates colonic inflammation in murine colitis models with reduced tissue damage and inflammatory cytokine levels.
Luger et al. (2003) reviewed the anti-inflammatory and antimicrobial properties of alpha-MSH C-terminal tripeptide KPV.
Dalmasso et al. (2008) demonstrated KPV-loaded nanoparticles reduced colonic inflammation when delivered orally in a murine colitis model.
In vitro anti-inflammatory studies use 10-100 micromolar. Colitis studies in mice used 0.5-2 mg/kg. Antimicrobial activity observed at 50-200 micromolar.
Storage & Handling
Store lyophilized powder at -20C. KPV is a very small tripeptide and is relatively stable. Reconstituted solution at 2-8C, use within 21 days.
Frequently Asked Questions
What is KPV?
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH with potent anti-inflammatory and antimicrobial properties. It works by entering cells and directly blocking NF-kB activation, without requiring melanocortin receptor binding.
Does KPV cause tanning like alpha-MSH?
No. KPV does not activate MC1R (the melanocortin receptor responsible for melanogenesis/tanning). Its anti-inflammatory mechanism is intracellular and receptor-independent.
What is the IBD research connection?
KPV has shown efficacy in murine colitis models, reducing inflammation and protecting intestinal mucosa. Research has also explored oral delivery using nanoparticles that target the inflamed colon.
Source KPV (Lysine-Proline-Valine) for your research
LL-37 is the only human cathelicidin antimicrobial peptide, derived from the C-terminal cleavage of the 18-kDa precursor protein hCAP18 by proteinase 3. It is a 37-amino-acid amphipathic alpha-helical peptide produced by neutrophils, macrophages, epithelial cells, and other cell types as part of the innate immune defense.
LL-37's antimicrobial mechanism involves direct membrane disruption of microbial cells. Its amphipathic structure — with a hydrophobic face and a cationic (positively charged) face — enables it to insert into negatively charged microbial membranes, causing pore formation and cell lysis. It is active against a broad spectrum of Gram-positive and Gram-negative bacteria, fungi, and enveloped viruses. Crucially, LL-37 also disrupts bacterial biofilms at sub-bactericidal concentrations, a property that distinguishes it from many conventional antibiotics.
Beyond direct antimicrobial activity, LL-37 serves as a potent immunomodulator. It recruits immune cells to infection sites by acting as a chemoattractant for neutrophils, monocytes, and T-cells via the formyl peptide receptor-like 1 (FPRL1). It promotes wound healing by stimulating angiogenesis and re-epithelialization. LL-37 also modulates Toll-like receptor signaling, enhancing the immune response to bacterial products while dampening potentially harmful excessive inflammatory responses.
Key Research Findings
Hancock & Sahl (2006) reviewed antimicrobial peptides including LL-37 as key effectors of innate immunity with direct microbicidal and immunomodulatory functions.
Overhage et al. (2008) demonstrated LL-37 inhibits Pseudomonas aeruginosa biofilm formation at 0.5 mcg/mL — well below its bactericidal concentration — through interference with quorum sensing.
Heilborn et al. (2003) showed LL-37 is upregulated during wound healing and promotes re-epithelialization of human skin wounds.
Vandamme et al. (2012) reviewed LL-37's dual role as antimicrobial agent and wound healing promoter.
In vitro antimicrobial studies use 1-32 mcg/mL. Anti-biofilm activity observed at 0.5-4 mcg/mL. Wound healing studies in animals use topical application of 10-100 mcg/wound.
Storage & Handling
Store lyophilized powder at -20C. LL-37 is susceptible to proteolytic degradation; reconstitute in sterile water and store at 2-8C for short-term use. Avoid repeated freeze-thaw cycles.
Frequently Asked Questions
What is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide that serves as a key component of innate immune defense. It has direct antimicrobial, anti-biofilm, and wound healing properties.
How does LL-37 fight biofilms?
LL-37 disrupts bacterial biofilm formation at concentrations below its bactericidal threshold. This is significant because biofilms are a major cause of antibiotic-resistant chronic infections. The mechanism involves interference with bacterial quorum sensing and surface attachment.
Is LL-37 only antimicrobial?
No. Beyond direct microbial killing, LL-37 modulates immune cell recruitment, promotes wound healing via angiogenesis and re-epithelialization, and regulates inflammatory responses through Toll-like receptor signaling modulation.
SS-31 (elamipretide) is a synthetic cell-permeable tetrapeptide developed by Hazel Szeto at Weill Cornell Medical College. It is designed to target the inner mitochondrial membrane by selectively binding to cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin plays a critical structural role in organizing electron transport chain (ETC) complexes into supercomplexes (respirasomes) that enable efficient electron transfer.
By binding cardiolipin, SS-31 stabilizes the cristae structure and ETC supercomplex organization, improving the efficiency of oxidative phosphorylation. This reduces electron leak and consequently decreases mitochondrial reactive oxygen species (ROS) production. Importantly, SS-31 does not act as a conventional antioxidant that scavenges ROS after they are produced — instead, it prevents excess ROS generation at the source by optimizing ETC function.
SS-31 has shown therapeutic potential across multiple organ systems in preclinical and clinical studies. It reduces infarct size in cardiac ischemia-reperfusion injury, protects renal tubular cells from ischemic damage, improves skeletal muscle function in aged animals, and reverses age-related mitochondrial dysfunction. It has advanced to Phase II/III clinical trials for heart failure (Barth syndrome, primary mitochondrial myopathy, and heart failure with preserved ejection fraction).
Key Research Findings
Szeto (2006) demonstrated SS-31 concentrates >1000-fold in mitochondria and selectively reduces mitochondrial ROS without affecting cytosolic signaling ROS.
Birk et al. (2014) showed SS-31 binds cardiolipin and stabilizes cytochrome c function, improving electron transport efficiency and reducing oxidative damage.
Siegel et al. (2013) demonstrated SS-31 reduced infarct size by 50% in a canine model of ischemia-reperfusion injury.
Campbell et al. (2019) reported that SS-31 improved 6-minute walk distance in patients with primary mitochondrial myopathy in a Phase II trial.
Clinical trials used 0.01-0.25 mg/kg IV or 4-40 mg SC daily. Mouse studies used 1-3 mg/kg IP. The typical research dose in preclinical cardiac studies is 0.1-3 mg/kg.
Storage & Handling
Store lyophilized powder at -20C. Reconstituted solution should be refrigerated at 2-8C and used within 14 days. SS-31 is relatively stable due to the D-amino acid and modified tyrosine.
Frequently Asked Questions
What is SS-31?
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. It improves electron transport chain efficiency and reduces mitochondrial oxidative stress. It has advanced to clinical trials for heart failure and mitochondrial myopathy.
How does SS-31 differ from conventional antioxidants?
Conventional antioxidants scavenge ROS after they are produced. SS-31 prevents excess ROS at the source by optimizing ETC supercomplex organization through cardiolipin binding. This is a fundamentally different and more targeted approach.
What clinical trials has SS-31 entered?
SS-31 (as elamipretide) has entered Phase II/III clinical trials for Barth syndrome (a cardiolipin deficiency disorder), primary mitochondrial myopathy, heart failure with preserved ejection fraction, and renal ischemia protection.
Glutathione (GSH) is a tripeptide (gamma-glutamylcysteinylglycine) that serves as the body's most abundant intracellular antioxidant. It is present in millimolar concentrations in virtually all mammalian cells, with particularly high levels in the liver, where it plays a central role in detoxification and xenobiotic metabolism.
GSH functions as the primary substrate for glutathione peroxidase (GPx), which neutralizes hydrogen peroxide and lipid hydroperoxides. In this reaction, reduced GSH is oxidized to GSSG (glutathione disulfide), which is then regenerated by glutathione reductase using NADPH. The GSH/GSSG ratio is a key indicator of cellular redox status — a declining ratio indicates oxidative stress.
Beyond direct antioxidant activity, GSH is essential for Phase II hepatic detoxification via glutathione S-transferases (GSTs), which conjugate glutathione to electrophilic xenobiotics, drugs, and carcinogens for elimination. GSH also supports immune function — lymphocyte proliferation and natural killer cell activity depend on adequate GSH levels. Wu et al. demonstrated that GSH depletion impairs T-cell function, while supplementation restores immune responses. Glutathione levels decline with age, chronic disease, and environmental toxin exposure, making GSH status a biomarker of overall health.
Key Research Findings
Wu et al. (2004) reviewed glutathione metabolism and its critical role in immune cell function, demonstrating that GSH depletion impairs lymphocyte proliferation and NK cell activity.
Richie et al. (2015) showed oral glutathione supplementation (250-1000 mg/day) increased blood GSH levels and reduced oxidative stress markers in a randomized controlled trial.
Forman et al. (2009) reviewed glutathione as a key determinant of cellular redox signaling and its role in regulating transcription factors including NF-kB and AP-1.
Sinha et al. (2018) demonstrated IV glutathione improved skin melanin index in a clinical trial, supporting its use in dermatological research.
Oral studies use 250-1000 mg/day. IV protocols use 600-2400 mg per session. The 600mg vial provides a standard IV research dose.
Storage & Handling
Store lyophilized powder at -20C, protected from light and moisture. Reduced glutathione oxidizes readily; minimize air exposure. Reconstitute immediately before use. Store reconstituted solution at 2-8C for no more than 24 hours.
Frequently Asked Questions
What is Glutathione?
Glutathione is a tripeptide (Glu-Cys-Gly) that is the body's most abundant intracellular antioxidant. It neutralizes free radicals, supports liver detoxification, maintains immune function, and regulates cellular redox status.
Why does glutathione decline with age?
Multiple factors: reduced synthesis capacity, increased oxidative stress consumption, decreased nutrient intake of precursors (especially cysteine), and chronic inflammation. Glutathione levels at age 60 are approximately 50% of levels at age 20.
What is the difference between reduced and oxidized glutathione?
Reduced glutathione (GSH) is the active antioxidant form. When it neutralizes free radicals, it becomes oxidized glutathione (GSSG). The cell regenerates GSH from GSSG using NADPH. The GSH/GSSG ratio is a key measure of cellular health.
Kisspeptin is a neuropeptide product of the KISS1 gene that serves as a critical regulator of the hypothalamic-pituitary-gonadal (HPG) axis. It was discovered in 2003 by two independent groups (de Roux et al. and Seminara et al.) who identified loss-of-function mutations in the kisspeptin receptor (GPR54/KISS1R) as a cause of hypogonadotropic hypogonadism — failure to undergo puberty due to absent GnRH signaling.
Kisspeptin is the most potent known stimulator of gonadotropin-releasing hormone (GnRH) secretion. Kisspeptin neurons in the hypothalamic arcuate nucleus and anteroventral periventricular nucleus express KISS1R and project directly to GnRH neurons. Upon kisspeptin binding, KISS1R activation stimulates GnRH neurons to release GnRH into the portal circulation, which in turn triggers LH and FSH release from the anterior pituitary.
Kisspeptin-10 is the minimal bioactive C-terminal fragment (amino acids 45-54 of the full 54-amino-acid kisspeptin-54) that retains full KISS1R binding and activation. Research has explored kisspeptin as a diagnostic tool for reproductive disorders and as a potential therapeutic for infertility. Dhillo et al. demonstrated that kisspeptin-54 infusion potently stimulates LH secretion in healthy men and women, and subsequent work has explored its use in triggering oocyte maturation for IVF without the risk of ovarian hyperstimulation syndrome.
Key Research Findings
Seminara et al. (2003) identified KISS1R mutations as a cause of hypogonadotropic hypogonadism, establishing kisspeptin as essential for puberty onset and reproductive function.
Dhillo et al. (2005) demonstrated that kisspeptin-54 infusion potently stimulates LH and FSH secretion in healthy male volunteers.
Abbara et al. (2017) showed kisspeptin can safely trigger oocyte maturation in IVF protocols, potentially eliminating the risk of ovarian hyperstimulation syndrome.
De Roux et al. (2003) independently identified GPR54/KISS1R mutations in idiopathic hypogonadotropic hypogonadism families.
Human studies used IV infusions of kisspeptin-54 at 0.1-3.1 nmol/kg/hr. Kisspeptin-10 bolus studies used 0.3-10 nmol/kg IV. Subcutaneous dosing has also been explored.
Storage & Handling
Store lyophilized powder at -20C. Reconstituted solution should be refrigerated at 2-8C and used within 14 days. Kisspeptin is susceptible to oxidation; minimize air exposure.
Frequently Asked Questions
What is Kisspeptin?
Kisspeptin is a neuropeptide that serves as the master upstream regulator of the reproductive hormone cascade. It stimulates GnRH release, which triggers LH and FSH secretion. Its discovery in 2003 was a breakthrough in reproductive endocrinology.
What is the connection to puberty?
Loss-of-function mutations in the kisspeptin receptor cause failure to undergo puberty. Kisspeptin signaling is the 'on switch' for the HPG axis at puberty onset, and it continues to regulate reproductive function throughout life.
What is the IVF application?
Kisspeptin can trigger oocyte maturation during IVF without the risk of ovarian hyperstimulation syndrome (OHSS), a potentially dangerous complication of standard hCG triggers. This is being actively researched as a safer alternative.
Source Kisspeptin-10 (Metastin 45-54) for your research